Abstract
To enable real-time imaging of boron delivery with cellular resolution, a series of fluorescent [10B] compounds was developed via a one-step synthesis using cost-effective, scalable reagents. The tumor-targeting agent, [10B]-a11, allowed noninvasive monitoring to identify the optimal time point for boron neutron capture therapy (BNCT) based on peak tumor accumulation. Fluorescence imaging analysis revealed a heterogeneous intratumoral distribution of [10B]-a11, confirming that macroscopic accumulation does not equate to microscopic uniformity and emphasizing the need for improved tumor penetration in next-generation boron carriers. Furthermore, [10B]-a11 demonstrated efficacy for fluorescence-guided surgery in prostate cancer, suggesting a potential synergistic strategy to combine precise resection with BNCT for improved therapeutic outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 16964-16974 |
| Number of pages | 11 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 69 |
| Issue number | 14 |
| DOIs | |
| State | Published - 23 Jul 2026 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'The One-Step Incorporation of Boron-10 Atom into Prostate Cancer-Targeted Fluorophores for Visualizing In Vivo Boron-10 Delivery and Intratumoral Distribution with Cellular Resolution'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver